Cassava Sciences Inc (SAVA)

[phil713]

Tomorrow is the day when PTIE meets with the FDA.

Hoping the meeting is favorable.

Based on a fair, neutral and impartial review of data, there is overwhelming evidence that REMOXY may be less abusable than marketed extended-release oxycodone products;

When corrected for math errors, material mistakes and misrepresentations made by FDA during a June 2018 Advisory Committee Meeting, REMOXY has properties that may deter against common methods of abuse, such as injection abuse; and

REMOXY meets all evidentiary standards for drug approval and its proposed indication.
For these and other reasons, Pain Therapeutics has requested a neutral re-examination of its data, further discussion and a fair resolution of this matter. The FDA and the Company have agreed to meet in person on January 31, 2019 to discuss this matter.

https://ih.advfn.com/stock-market/NASDAQ/pain-therapeutics-PTIE/stock-news/79002246/pain-therapeutics-announces-two-new-peer-reviewed